{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:10:55Z","timestamp":1793502655292,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtct.2024.01.069","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T10:16:27Z","timestamp":1705832187000},"page":"402.e1-402.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-2061","authenticated-orcid":false,"given":"Tejaswini","family":"Dhawale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-9535","authenticated-orcid":false,"given":"Kofi","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-5920","authenticated-orcid":false,"given":"Anna","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Traeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-3280","authenticated-orcid":false,"given":"Ashley M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-5703","authenticated-orcid":false,"given":"Mitchell W.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1235-0668","authenticated-orcid":false,"given":"Katherine","family":"Holmbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-967X","authenticated-orcid":false,"given":"Joanna","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Nabily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astha","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-9644","authenticated-orcid":false,"given":"Hermioni L.","family":"Amonoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-1495","authenticated-orcid":false,"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2024.01.069_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.01.069_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.01.069_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2024.01.069_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.01.069_bib0005","unstructured":"FDA. Approved cellular and gene therapy products. 2022; Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed March 16, 2023."},{"issue":"19","key":"10.1016\/j.jtct.2024.01.069_bib0006","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"issue":"41","key":"10.1016\/j.jtct.2024.01.069_bib0007","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1200\/EDBK_320085","article-title":"CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions","author":"Gill","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.069_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.069_bib0009","unstructured":"Leukemia & Lymphoma Society. Chimeric Antiven Receptor (CAR) T-Cell Therapy. 2023; Available at: https:\/\/www.lls.org\/treatment\/types-treatment\/immunotherapy\/chimeric-antigen-receptor-car-t-cell-therapy. Accessed: October 2, 2023."},{"key":"10.1016\/j.jtct.2024.01.069_bib0010","unstructured":"American Cancer Society. CAR T-cell therapy and its side effects. Available at: https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/car-t-cell1.html. Accessed October 2, 2023"},{"issue":"1","key":"10.1016\/j.jtct.2024.01.069_bib0011","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.1997.15.1.330","article-title":"Trading treatment toxicity for survival in locally advanced non-small cell lung cancer","volume":"15","author":"Brundage","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2024.01.069_bib0012","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pon.1450","article-title":"Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer","volume":"18","author":"Hirose","year":"2009","journal-title":"Psychooncology"},{"issue":"7161","key":"10.1016\/j.jtct.2024.01.069_bib0013","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.317.7161.771","article-title":"Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews","volume":"317","author":"Silvestri","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.069_bib0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/02692163221138880","article-title":"A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: recommendations for service development and implications for palliative care teams","volume":"37","author":"Stenson","year":"2023","journal-title":"Palliat Med"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.069_bib0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.069_bib0016","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/jpm.2020.0138","article-title":"Chimeric antigen receptor T cell immunotherapy: what you need to know #393","volume":"23","author":"Sedhom","year":"2020","journal-title":"J Palliat Med"},{"issue":"10","key":"10.1016\/j.jtct.2024.01.069_bib0017","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269216320916154","article-title":"Palliative care in the context of immune and targeted therapies: a qualitative study of bereaved carers\u2019 experiences in metastatic melanoma","volume":"34","author":"Fox","year":"2020","journal-title":"Palliat Med"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.069_bib0018","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.jtct.2024.01.069_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.069_bib0020","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1200\/OP.21.00388","article-title":"Communicating the information needed for treatment decision making among patients with pancreatic cancer receiving preoperative therapy","volume":"18","author":"Lee","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"23","key":"10.1016\/j.jtct.2024.01.069_bib0021","first-page":"00074","article-title":"Patient confidence and information preferences during the treatment decision-making process: results from a large multiple myeloma patient survey across 12 countries in Europe and Israel","volume":"S2152-2650","author":"Mellqvist","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.069_bib0022","first-page":"377","article-title":"Implementing and evaluating shared decision making in oncology practice","volume":"64","author":"Kane","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.jtct.2024.01.069_bib0023","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/annonc\/mdt193","article-title":"\u2018One also needs a bit of trust in the doctor ... \u2019: a qualitative interview study with pancreatic cancer patients about their perceptions and views on information and treatment decision-making","volume":"24","author":"Schildmann","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.01.069_bib0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.jtct.2024.01.069_bib0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"issue":"7","key":"10.1016\/j.jtct.2024.01.069_bib0026","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1089\/jpm.2018.0487","article-title":"A qualitative study of serious illness conversations in patients with advanced cancer","volume":"22","author":"Geerse","year":"2019","journal-title":"J Palliat Med"},{"key":"10.1016\/j.jtct.2024.01.069_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100692","article-title":"Illness and prognostic understanding in patients with hematologic malignancies","volume":"45","author":"Gray","year":"2021","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.069_bib0028","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/SPC.0000000000000459","article-title":"Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancer","volume":"13","author":"Hui","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.069_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-020-00810-3","article-title":"The importance of prognostication: impact of prognostic predictions, disclosures, awareness, and acceptance on patient outcomes","volume":"22","author":"Hui","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2024.01.069_bib0030","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1002\/cam4.3102","article-title":"Patient and clinician experience of a serious illness conversation guide in oncology: a descriptive analysis","volume":"9","author":"Paladino","year":"2020","journal-title":"Cancer Med"},{"issue":"14","key":"10.1016\/j.jtct.2024.01.069_bib0031","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/jama.2017.1964","article-title":"Vital directions for health and health care: priorities from a National Academy of Medicine Initiative","volume":"317","author":"Dzau","year":"2017","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jtct.2024.01.069_bib0032","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMp1908153","article-title":"Goal-concordant care: searching for the holy grail","volume":"381","author":"Halpern","year":"2019","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1016\/j.jtct.2024.01.069_bib0033","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1089\/jpm.2017.0459","article-title":"Achieving goal-concordant care: a conceptual model and approach to measuring serious illness communication and its impact","volume":"21","author":"Sanders","year":"2018","journal-title":"J Palliat Med"},{"issue":"4481","key":"10.1016\/j.jtct.2024.01.069_bib0034","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.7455683","article-title":"The framing of decisions and the psychology of choice","volume":"211","author":"Tversky","year":"1981","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.069_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0895-4356(89)90085-1","article-title":"Effects of framing and level of probability on patients\u2019 preferences for cancer chemotherapy","volume":"42","author":"O'Connor","year":"1989","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.069_bib0036","doi-asserted-by":"crossref","first-page":"e99778","DOI":"10.1371\/journal.pone.0099778","article-title":"Peri-transplant psychosocial factors and neutrophil recovery following hematopoietic stem cell transplantation","volume":"9","author":"Knight","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.069_bib0037","first-page":"797","article-title":"Relationships among symptoms, psychosocial factors, and health-related quality of life in hematopoietic stem cell transplant survivors","volume":"23","author":"Kenzik","year":"2015","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.jtct.2024.01.069_bib0038","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41409-021-01296-9","article-title":"A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial","volume":"56","author":"Amonoo","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.01.069_bib0039","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/08870446.2021.2006197","article-title":"A systematic review of the effects of positive versus negative framing on cancer treatment decision making","volume":"38","author":"Tang","year":"2023","journal-title":"Psychol Health"},{"issue":"8","key":"10.1016\/j.jtct.2024.01.069_bib0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.6004\/jnccn.2020.7678","article-title":"Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy","volume":"19","author":"Johnson","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"36","key":"10.1016\/j.jtct.2024.01.069_bib0041","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2007.12.4180","article-title":"Oncologist communication about emotion during visits with patients with advanced cancer","volume":"25","author":"Pollak","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:01:58Z","timestamp":1762639318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724001623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666636724001623"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.069","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}